Phase 1b/2 Study of IV Sarilumab in Adult With RA

计划入组 140 人 · 首次发布于 2026 年 7 月 15 日

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

计划入组 39 人 · 首次发布于 2024 年 10 月 9 日

PHASE 1B/2 STUDY OF ITU V937 IN COMBINATION WITH PEMBROLIZUMAB

计划入组 2 人

LTX-001

Golexanolone

C₂₁H₃₁NO₂

Fostroxacitabine bralpamide

C₂₂H₃₀BrN₄O₈P

Context Therapeutics

United States

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

Evorpacept Enters Phase 2 Trial for Platinum-Resistant Ovarian Cancer

Aptevo's Mipletamig Achieves 100% Remission Rate in Phase 1b/2 AML Trial

Navenibart Shows Promise in Reducing Hereditary Angioedema Attacks in Phase 1b/2 Trial